Clinical relevance of systematic phenotyping and exome sequencing in patients with short stature

Nadine N Hauer, Bernt Popp, Eva Schoeller, Sarah Schuhmann, Karen E Heath, Alfonso Hisado-Oliva, Patricia Klinger, Cornelia Kraus, Udo Trautmann, Martin Zenker, Christiane Zweier, Antje Wiesener, Rami Abou Jamra, Erdmute Kunstmann, Dagmar Wieczorek, Steffen Uebe, Fulvia Ferrazzi, Christian Büttner, Arif B Ekici, Anita Rauch, Heinrich Sticht, Helmuth-Günther Dörr, André Reis, Christian T Thiel, Nadine N Hauer, Bernt Popp, Eva Schoeller, Sarah Schuhmann, Karen E Heath, Alfonso Hisado-Oliva, Patricia Klinger, Cornelia Kraus, Udo Trautmann, Martin Zenker, Christiane Zweier, Antje Wiesener, Rami Abou Jamra, Erdmute Kunstmann, Dagmar Wieczorek, Steffen Uebe, Fulvia Ferrazzi, Christian Büttner, Arif B Ekici, Anita Rauch, Heinrich Sticht, Helmuth-Günther Dörr, André Reis, Christian T Thiel

Abstract

PurposeShort stature is a common condition of great concern to patients and their families. Mostly genetic in origin, the underlying cause often remains elusive due to clinical and genetic heterogeneity.MethodsWe systematically phenotyped 565 patients where common nongenetic causes of short stature were excluded, selected 200 representative patients for whole-exome sequencing, and analyzed the identified variants for pathogenicity and the affected genes regarding their functional relevance for growth.ResultsBy standard targeted diagnostic and phenotype assessment, we identified a known disease cause in only 13.6% of the 565 patients. Whole-exome sequencing in 200 patients identified additional mutations in known short-stature genes in 16.5% of these patients who manifested only part of the symptomatology. In 15.5% of the 200 patients our findings were of significant clinical relevance. Heterozygous carriers of recessive skeletal dysplasia alleles represented 3.5% of the cases.ConclusionA combined approach of systematic phenotyping, targeted genetic testing, and whole-exome sequencing allows the identification of the underlying cause of short stature in at least 33% of cases, enabling physicians to improve diagnosis, treatment, and genetic counseling. Exome sequencing significantly increases the diagnostic yield and consequently care in patients with short stature.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart gene discovery approach. We built a study group of 565 individuals with short stature or growth retardation (Table 1). Systematic phenotyping and targeted diagnostic testing of common and recognizable causes in all 565 patients led to a diagnostic yield of 13.6% (Supplementary Table 1). Detailed information about the systematic phenotyping is provided in the Methods section in the Supplementary Data. For 200 representative individuals where no underlying cause could be determined (Table 1), we performed whole-exome sequencing, which increased the diagnostic yield by 17% up to 33% by the identification of mutations in known short stature–associated genes (Table 2, Supplementary Tables 3–4). Genotype–phenotype re-evaluation confirmed that these patients present with only part of the characteristic symptomatology. The additional diagnostic yield already had direct effects in preventive measures, symptomatic and targeted treatment in 15.5% of the 200 exome-sequenced patients (Table 4 and Supplementary Table S6).

References

    1. on behalf of the American College of Medical Genetics (ACMG) Professional Practice and Guidelines CommitteeSeaver LH on behalf of the American College of Medical Genetics (ACMG) Professional Practice and Guidelines Committee. ACMG practice guideline: genetic evaluation of short stature. Genet Med. 2009;11:465–470.
    1. Rauch A, Thiel CT, Schindler D et al. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science. 2008;319:816–819.
    1. Argente J. Challenges in the management of short stature. Horm Res Paediatr 2016;85:2–10.
    1. Mumtaz S, Yildiz E, Jabeen S, Khan A, Tolun A, Malik S. RBBP8 syndrome with microcephaly, intellectual disability, short stature and brachydactyly. Am J Med Genet A 167A:3148–31522015.
    1. Green J, Cairns BJ, Casabonne D et al. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12:785–794.
    1. Shimizu Y, Imano H, Ohira T et al. Adult height and body mass index in relation to risk of total stroke and its subtypes: the circulatory risk in communities study. J Stroke Cerebrovasc Dis 2014;23:667–674.
    1. Amin N, Mushtaq T, Alvi S. Fifteen-minute consultation: the child with short stature. Arch Dis Child Educ Pract Ed 2015;100:180–184, 203.
    1. Rappold GA, Fukami M, Niesler B et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab 2002;87:1402–1406.
    1. Bonafe L, Cormier-Daire V, Hall C et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 2015;167A:2869–2892.
    1. Allen DB, Cuttler L. Clinical practice. Short stature in childhood—challenges and choices. N Engl J Med 2013;368:1220–1228.
    1. Cohen P, Rogol AD, Deal CL et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210–4217.
    1. Waldman LA, Chia DJ. Towards identification of molecular mechanisms of short stature. Int J Pediatr Endocrinol 20132013: 19.
    1. Visscher PM, Medland SE, Ferreira MA et al. Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings. PLoS Genet. 2006;2:e41.
    1. Wood AR, Esko T, Yang J et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet. 2014;46:1173–1186.
    1. Marouli E, Graff M, Medina-Gomez C et al. Rare and low-frequency coding variants alter human adult height. Nature. 2017;542:186–190.
    1. Guo MH, Shen Y, Walvoord EC et al. Whole exome sequencing to identify genetic causes of short stature. Horm Res Paediatr 2014;82:44–52.
    1. Zahnleiter D, Uebe S, Ekici AB et al. Rare copy number variants are a common cause of short stature. PLoS Genet. 2013;9:e1003365.
    1. Zahnleiter D, Hauer NN, Kessler K et al. MAP4-dependent regulation of microtubule formation affects centrosome, cilia, and Golgi architecture as a central mechanism in growth regulation. Hum Mutat. 2015;36:87–97.
    1. Wit JM, Oostdijk W, Losekoot M, van Duyvenvoorde HA, Ruivenkamp CA, Kant SG. Mechanisms in endocrinology: novel genetic causes of short stature. Eur J Endocrinol 2016;174:R145–R173.
    1. Delude CM. Deep phenotyping: the details of disease. Nature. 2015;527:S14–S15.
    1. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
    1. Schubbert S, Zenker M, Rowe SL et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38:331–336.
    1. Lederer D, Grisart B, Digilio MC et al. Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am J Hum Genet 2012;90:119–124.
    1. Miyake N, Mizuno S, Okamoto N et al. KDM6A point mutations cause Kabuki syndrome. Hum Mutat. 2013;34:108–110.
    1. Moog U, Bierhals T, Brand K et al. Phenotypic and molecular insights into CASK-related disorders in males. Orphanet J Rare Dis 2015;10:44.
    1. Tompson SW, Merriman B, Funari VA et al. A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan. Am J Hum Genet 2009;84:72–79.
    1. Hisado-Oliva A, Garre-Vazquez AI, Santaolalla-Caballero F et al. Heterozygous NPR2 mutations cause disproportionate short stature, similar to Leri-Weill dyschondrosteosis. J Clin Endocrinol Metab 2015;100:E1133–E1142.
    1. Vasques GA, Amano N, Docko AJ et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. J Clin Endocrinol Metab 2013;98:E1636–E1644.
    1. Quintos JB, Guo MH, Dauber A. Idiopathic short stature due to novel heterozygous mutation of the aggrecan gene. J Pediatr Endocrinol Metab 2015;28:927–932.
    1. Bartels CF, Bukulmez H, Padayatti P et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004;75:27–34.
    1. Posey JE, Harel T, Liu P et al. Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med 2017;376:21–31.
    1. Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev 2010;18:92–108.
    1. Ali O, Wyatt D. Therapy of growth disorders. Curr Opin Endocrinol Diabetes Obes 2011;18:3–8.
    1. Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. Pediatr Clin North Am 2011;58:1141–1165, x.
    1. Maass PG, Aydin A, Luft FC et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet. 2015;47:647–653.
    1. Movsesian M. Novel approaches to targeting PDE3 in cardiovascular disease. Pharmacol Ther 2016;163:74–81.
    1. Carmichael CM, McGue M. A cross-sectional examination of height, weight, and body mass index in adult twins. J Gerontol. A Biol Sci Med Sci 1995;50:B237–B244.
    1. Silventoinen K, Sammalisto S, Perola M et al. Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res 2003;6:399–408.
    1. Silventoinen K. Determinants of variation in adult body height. J Biosoc Sci 2003;35:263–285.
    1. de Ligt J, Willemsen MH, van Bon BW et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012;367:1921–1929.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel